Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sanofi, Takeda form Diabetes Collaboration in Japan

Published: Wednesday, July 02, 2014
Last Updated: Wednesday, July 02, 2014
Bookmark and Share
Companies have entered into an agreement to build a collaborative system within Japan in the field of diabetes awareness and education.

In the long history of diabetes treatment, both Sanofi and Takeda have brought to market numerous therapeutic drugs to treat diabetes over the years and have built up abundant knowledge and experience. By establishing this partnership, the two companies aim to offer more treatment solutions and information to healthcare professionals addressing diversified medical needs of people with diabetes. Through the agreement the two companies will also be able to expand educational activities regarding the disease.

The 2012 National Health and Nutrition Survey by the Ministry of Health, Labour and Welfare estimated that some 9.5 million Japanese are strongly suspected of having diabetes. The Ministry also predicts that the number of Japanese with diabetes will reach 15 million by 2025. One in every four people in Japan is said to be pre-diabetic, and of those who are strongly suspected of be diabetic, approximately 30% have never received sufficient treatment, according to the survey results.

To address challenges faced by diabetes patients, their families, healthcare professionals and the government, the two companies will uphold a vision that we aim to become the most trusted partners of healthcare professionals and diabetes patients in Japan. The agreement will develop solutions focused in the following three areas:

Raise public awareness of diabetes and educate on how to prevent diabetes, including lifestyle management.

Provide educational support to patients to emphasize the importance of dietary and exercise therapies and appropriate drug treatment.

Provide healthcare professionals with comprehensive information on diabetes care.

"Diabetes is too large and complex an issue for a single company, single doctor or single government to resolve on its own. Closely aligning efforts at all levels is essential to achieve a breakthrough in preventing, diagnosing and treating diabetes. To this end, we are excited to join forces with Takeda, Japan's largest pharmaceutical company and a leader in diabetes, to create this new and unique agreement to expand existing and create new approaches to improving patient care and, ultimately, improving outcomes for Japanese living with diabetes,” stated Jez Moulding, President and Representative Director, Sanofi K.K., Senior Vice President, Japan & Pacific Region

"Many effective solutions for diabetes treatment have been brought to market in the last 20 years, but many patients are still unable to meet their blood sugar control targets and many still experience complications," said Masato Iwasaki, Ph.D., Senior Vice President, Pharmaceutical Marketing Division of Takeda. "This close agreement between two leading companies in the field of diabetes holds great significance for finding solutions for diabetes treatments based on a mutual understanding of each other's vision and therapies. With such an excellent partner, we are confident that we will be better equipped to facilitate diabetes care for patients based on their individual needs."

The agreement involves no initial payment or other compensation. The manufacturing and marketing rights holder of each company’s respective products will conduct their own product promotion and collection and dissemination of product safety information.

In addition to this agreement, both parties agree to start formulation development studies of a fixed dose combination of tofogliflozin (product name: Apleway®) and alogliptin (product name: Nesina®).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Takeda, Altos Announce Partnership
Partnership aims to develop promising compound for the treatment of gastroparesis.
Thursday, July 07, 2016
Exosome Diagnostics, Takeda Enter Partnership
Exosome Diagnostics has entered into a collaboration with Takeda Pharmaceuticals International Co. to develop an exosomal RNA sequencing platform for biomarkers.
Friday, July 01, 2016
TB Alliance, Takeda Advance TB Therapy Program
The companies have announced that they have entered into an agreement that further explores hits generated from a high-throughput screening program conducted to find novel compounds to improve treatment of tuberculosis (TB).
Thursday, June 23, 2016
Takeda Initiates World's First Norovirus Vaccine Field Trial
Vaccine candidate will target the leading cause of acute gastroenteritis around the globe.
Wednesday, June 22, 2016
Takeda Receives $38 Million Grant from the Gates Foundation
The grant has been awareded to support polio eradication in developing countries.
Wednesday, May 11, 2016
Takeda, NsGene Partner
Takeda Pharmaceutical and NsGene, Inc. have announced a research agreement to develop encapsulated cell therapies for the potential treatment of Parkinson’s disease.
Thursday, January 14, 2016
Takeda Acquires U.S. Biologics Manufacturing Facility
Takeda Pharmaceutical Company Limited has announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc.
Thursday, January 07, 2016
Takeda, Enterome Enter Drug Discovery Collaboration
Takeda and Enterome have announced they have entered into a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome).
Thursday, January 07, 2016
Takeda, Cour Partner
Takeda and Cour have announced a partnership to research and develop novel immune modulating therapies for the potential treatment of celiac disease.
Wednesday, December 09, 2015
Gencia and Takeda Partner On Mitochondrial Therapeutics
The companies announced have a partnership to develop a new class of small molecule drugs as potential treatments for hematological and inflammatory diseases.
Friday, September 11, 2015
Takeda, Sanford-Burnham Launch Heart Failure Collaboration
The partners will study the potential role of several gene regulatory proteins as targets for new treatments.
Friday, May 29, 2015
Takeda Licenses Rights to Use ImmunoGen's ADC Technology
To develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets.
Friday, March 27, 2015
Takeda Announces Formalization of Takeda Oncology
Enhance discovery, development and global commercialization of cancer medicines.
Friday, December 12, 2014
Takeda Buys Vaccines Specialist Inviragen
Obtains promising vaccine candidates against dengue and hand, foot and mouth disease, advancing Takeda's commitment to vaccines and global health.
Thursday, May 09, 2013
Takeda to Acquire URL Pharma
Acquisition expands U.S. business, leadership in gout.
Thursday, April 12, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
JPK NanoWizard® Applied to a Wide Range of Research
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Protein Boosts Rice Yield by 54%
Over-expression of a natural protein in rice plants led to a 54% increase in crop yield and 40% increase in nitrogen-use efficiency.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Soil Nitrogen Age Important for Precision Agriculture
Calculating the age of nitrogen in corn and soybean fields could lead to improved fertilizer application techniques.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!